Objectives: To assess the long-term efficacy and safety of alfuzosin 10 mg OD in patients with symptomatic BPH. Methods: Patients (>50 years) were randomised to alfuzosin 10 mg OD, alfuzosin 2.5. mg t.i.d. or placebo for 3 months. Open-label alfuzosin 10 mg OD was continued for up to 1 year. Efficacy assessments included the International Prostate Symptom Score (I-PSS) and quality of life index and uroflowmetry. Results: At 3 months, there was a significant reduction in I-PSS and a significant improvement in peak flow rate for both alfuzosin groups compared with placebo (p < 0.05). Vasodilatory adverse experiences were more common in the alfuzosin 2.5 mg group than the 10 mg OD group. Improvements in symptoms and flow rate with alfuzosin 10 mg OD were maintained for up to 12 months. Conclusion: Alfuzosin 10 mg OD is an effective treatment for symptomatic BPH for at least 12 months, with a better cardiovascular safety profile than the immediate release formulation.

1.
Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
2.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
3.
Abrams P: Managing lower urinary tract symptoms in older men. Br Med J 1995;310:1113–1117.
4.
Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481–487.
5.
Pickard R, Emberton M, Neal DE: The management of men with acute urinary retention. Br J Urol 1998;81:712–720.
6.
Caine M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:641–649.
7.
Andersson KE: Uroselectivity; in Cockett ATK, Khoury AS, Aso Y, et al (eds): Proceedings of the 3rd Consultation on Benign Prostatic Hyperplasia, Monaco, June 1995. Paris, Scientific Communications International, 1996, pp 541–542.
8.
Shapiro E, Lepor H: The pathophysiology of clinical BPH. Urol Clin North Am 1998;22:375–386.
9.
Kirby R: Benign prostatic hyperplasia. Br Med J 1999;318:343–344.
10.
Lepor H: Alpha-adrenergic blockers: A promising medical alternative to prostatectomy? Rev Urol 1999;1:45–54.
11.
Cockett ATK, Aso Y, Denis L, et al: Recommendations of the International Consensus Committee; in Cockett ATK, Khoury AS, Aso Y, et al (eds): Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, June 1993. Paris, Scientific Communications International, 1993, pp 553–672.
12.
Eri LM, Tveter KJ: α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923–934.
13.
Narayan P, Tewari A: Overview of α-blocker therapy for benign prostatic hyperplasia. Urology 1998;51(suppl 4A):38–45.
14.
Caine M: The present role of alpha adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986;136:1–4.
15.
Teillac P, Delauche-Cavallier MC, Attali P: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992;70:58–64.
16.
Martorana G Giberti C, Di Silverio F, von Heland M, Rigatti P, Colombo R, Casadei G, Pacifico P: Effects of short treatment with the alpha-1-blocker alfuzosin on urodynamic/flow parameters in patients with BPH. Eur Urol 1997;32:47–53.
17.
Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, and the ALGEBI Study Group: Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997;31:190–198.
18.
Lukacs B, Grange JC, Comet D, McCarthy C, and the BPH Group in General Practice: Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate cancer and prostate diseases 1998;5:276–293.
19.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, and the BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991;337:1457–1461.
20.
McNeill SA, Hargreaves TB, Geffriaud-Ricouard C, Santini J-P, Roehrborn CG: Impact of alfuzosin on residual urine: Pooled analysis of 11 double-blind controlled studies. J Urol 2000;163 (suppl):219.
21.
McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreaves TB: Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo controlled trial. BJU Int 1999;84:622–627.
22.
Debruyne FMJ, Jardin A, Colloi D, Resel L, Witjes WPJ, Delauche-Cavallier MC, McCarthy C, Geffriaud-Ricouard C on behalf of the European ALFIN Study Group: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998;34:169–175.
23.
Rauch C, André F, Thénot J-P: Bioequivalence study of a new once a day controlled release alfuzosin formulation with the 5 mg twice daily formulation. J Urol 2000;163(suppl 4):306.
24.
Rauch C, Ahtoy P, Pinquier J-L, Dubruc C, Thénot J-P: Bioequivalence of a new once-a-day controlled-release alfuzosin formulation with the immediate-release formulation. Eur Urol 2000;37(suppl 2):119.
25.
Van Kerrebroeck P, Jardin A, Laval KU, van Cangh P and the ALFORTI Study Group: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000;37:306–313.
26.
Van Kerrebroeck P, Jardin A, Van Cangh P, Laval KU, Geffriaud-Ricouard C and the ALFORTI Study Group: 12-month safety and efficacy for a new once-a-day formulation of alfuzosin for symptomatic BPH. Eur Urol 2000;37(suppl 2):119.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.